Register
Login:
Share:
Email Facebook Twitter




SAR Share Chat - RSS Feed

Sareum Share Chat (SAR)



Share Price: 0.24Bid: 0.23Ask: 0.25Change: 0.015 (+6.67%)Riser - Sareum
Spread: 0.02Spread as %: 8.70%Open: 0.225High: 0.24Low: 0.225Yesterday’s Close: 0.225


Share Discussion for Sareum (SAR)


Thread ViewThread View
Please Login or Register to post messages
Posts per page:


pablo2
Posts: 7,075
Off Topic
Opinion:No Opinion
Price:0.48
View Thread (2)
Patent or Patience
22 Sep '14
One seems to need interminable patience with these bio stocks.

Will look back in this time next year - lol.
 
Hopkirk
Posts: 1,277
Off Topic
Opinion:No Opinion
Price:0.46
View Thread (2)
Patent
22 Sep '14
Remember, the more types of cancer that a drug can be used against, the more potential revenue it will make (still just potential, but human trials are due to start soon).

Here is a list of those targets from the patent...

In one embodiment, the treatment is treatment of: lung cancer, small cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, stomach cancer, bowel cancer, colon cancer, rectal cancer, colorectal cancer, thyroid cancer, breast cancer, ovarian cancer, endometrial cancer, prostate cancer, testicular cancer, liver cancer, kidney cancer, renal cell carcinoma, bladder cancer, pancreatic cancer, brain cancer, glioma, sarcoma, osteosarcoma, bone cancer, nasopharyngeal cancer (e.g., head cancer, neck cancer), skin cancer, squamous cancer, Kaposi's sarcoma, melanoma, malignant melanoma, lymphoma, or leukemia. 
In one embodiment, the treatment is treatment of: a carcinoma, for example a carcinoma of the bladder, breast, colon (e.g., colorectal carcinomas such as colon adenocarcinoma and colon adenoma), kidney, epidermal, liver, lung (e.g., adenocarcinoma, small cell lung cancer and non-small cell lung carcinomas), oesophagus, gall bladder, ovary, pancreas (e.g., exocrine pancreatic carcinoma), stomach, cervix, thyroid, prostate, skin (e.g., squamous cell carcinoma); a hematopoietic tumour of lymphoid lineage, for example leukemia, acute lymphocytic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non- Hodgkin's lymphoma, hairy cell lymphoma, or Burkett's lymphoma; a hematopoietic tumor of myeloid lineage, for example acute and chronic myelogenous leukemias, myelodysplasia syndrome, or promyelocytic leukemia; a tumour of mesenchymal origin, for example fibrosarcoma or habdomyosarcoma; a tumor of the central or peripheral nervous system, for example astrocytoma, neuroblastoma, glioma or schwannoma; melanoma; seminoma; teratocarcinoma; osteosarcoma; xenoderoma pigmentoum; keratoctanthoma; thyroid follicular cancer; or Kaposi's sarcoma.
wintzy
Posts: 293
Off Topic
Opinion:No Opinion
Price:0.46
Movement
22 Sep '14
A little bit of positive "admin" and this is up over 5%. For those watching and waiting, on real news this will rocket. That news is getting closer.
johnygreenfeet
Posts: 1,061
Off Topic
Opinion:No Opinion
Price:0.46
Patent
22 Sep '14
may be they wanted this before they could do a deal this could be a very interesting bit of news
The-Oracle
Posts: 418
Off Topic
Opinion:No Opinion
Price:0.46
CHK1 Patent Update 22nd Sept 2014
22 Sep '14
Sareum (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce that the European Office has issued notification of a grant of a patent for one of the inventions associated with the CHK1 cancer programme.

The patent* describes compounds that inhibit CHK1 kinase enzyme function and their potential to treat cancer, when administered alone or in combination with chemotherapy or radiotherapy. The CHK1 cancer programme is a co-development collaboration between the Cancer Research Technology Pioneer Fund, Sareum and BACIT Ltd.

This patent, which has also been granted in the USA, is part of a wide intellectual property estate which, if granted in its current form, would provide broad geographical protection for the CHK1 programme.

* Patent No. EP2288601

Sareum's CEO, Dr Tim Mitchell, commented: "The intellectual property that underpins the CHK1 cancer programme continues to develop, protecting the asset and enhancing its commercial value".
Num4
Posts: 598
Off Topic
Opinion:No Opinion
Price:0.45
Too big
22 Sep '14
How big is the jigsaw though?? And I think it's a double sided one..
stevej
Posts: 6,660
Off Topic
Opinion:No Opinion
Price:0.45
Rns
22 Sep '14
All good and protects program! You would need to prove your patient works to receive it so shows program coming along nicely and just awaiting approval for phase 1. Won't add anything to SP today as we already have US approval but another piece in the jigsaw to me. GLA
gezza
Posts: 1,008
Question
Opinion:Buy
Price:0.45
RNS
22 Sep '14
chk 1 update rns out this morning, any thoughts anyone ?
aa111
Posts: 954
Off Topic
Opinion:No Opinion
Price:0.45
cancer cure
20 Sep '14
hope sar can at least help to find a cure. closer to home I would really like to see some advance with an MS cure too. Is there any company related to sar having a go ?
Hopkirk
Posts: 1,277
Off Topic
Opinion:No Opinion
Price:0.45
View Thread (3)
RE: Response from Tim
20 Sep '14
Riz. Ask a question that can be answered and you will get an answer.

News will come when its ready. Not before.

Read the ICR article again. I'm not saying it's imminent but it is due soon.





Sign up for Live Prices


Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.